Genitourinary Cancer

Genitourinary Cancer

Prognostic Value of Immune-Related lncRNA Pairs in Patients With Bladder Cancer

Research establishes a novel model to predict the efficacy of immunotherapy regardless of expression.

World Journal of Surgical Oncology
Systemic Immune-Inflammation Index is a Promising Non-Invasive Biomarker for Predicting the Survival of Urinary System Cancers

This meta-analysis aimed to explore the prognostic significance of pre-treatment SII in tumours of the urinary system.

Annals of Medicine
Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients With Muscle-Invasive Bladder Cancer (EFFORT-MIBC)

Researchers work to stratify patients and guide further treatment decisions in order to improve the outcome of patients with primary MIBC.

BMC Cancer

Robotic-Assisted Radical Cystectomy Safe, Feasible for Octogenarians

Doctors compare mortality rates to find that RARC was associated with lower in-hospital mortality compared with open surgery even after controlling for patient and hospital characteristics.

Cancer Therapy Advisor
A Retrospective Multicenter Comparison of Conditional Cancer-Specific Survival Between Laparoscopic and Open Radical Nephroureterectomy in Locally Advanced Upper Tract Urothelial Carcinoma

Scientists compare the CCSS between ONU and LNU in patients with advanced UTUC after adjusting for the differential baseline characteristics by using propensity score matching.

Role of Hypermethylated-lncRNAs in the Prognosis of Bladder Cancer Patient

RRBS was conducted on five paired bladder cancer and normal adjacent tissues to screen for methylated-RNAs (including lncRNAs). 

Journal of International Medical Research
Biological Functions and Clinical Significance of Long Noncoding RNAs in Bladder Cancer

This study summarizes the functions and mechanisms, and clinical significance of lncRNAs in the oncogenesis and malignancy of human BCa within the last 10 years.

Cell Death Discovery
Quality of Life Among Germ-Cell Testicular Cancer Survivors: The Effect of Time Since Cancer Diagnosis

Research questions whether there are time-dependent effects of the disease and treatment on the age-adjusted QoL.

Trends of Incidence and Prognosis of Upper Tract Urothelial Carcinoma

Scientists estimate the incidence of UTUC based on age, sex and primary site and to establish a reliable and practical nomogram based on significant clinical factors...

The Clinical Implications and Molecular Mechanism of CX3CL1 Expression in Urothelial Bladder Cancer

Researchers evaluate the association between CX3CL1 and BCa and to investigate the underlying biological mechanisms involving CX3CL1 and its receptors in BCa.

Frontiers in Oncology
Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as a Prognostic Biomarker in Primary Non-Muscle-Invasive Bladder Cancer

Researchers evaluate the prognostic value of the AST/ALT ratio in primary NMIBC using PSM analysis.

BMC Urology
Metformin and Sodium Dichloroacetate Effects on Proliferation, Apoptosis, and Metabolic Activity Tested Alone and in Combination in a Canine Prostate and a Bladder Cancer Cell Line

This study aimed to investigate the effect of metformin on the metabolic activity and cell proliferation of canine carcinoma-derived tumor cell lines.

DD-MVAC vs Gemcitabine/Cisplatin for Muscle-Invasive Bladder Cancer

Scientists compare the efficacy of gemcitabine/cisplatin or dose-dense methotrexate, vinblastine, doxorubicin & dd-MVAC in patients with muscle-invasive bladder cancer. 

The ASCO Post
High Expression of SLC16A1 as a Biomarker to Predict Poor Prognosis of Urological Cancers

This study provided a potential molecular mechanism of the key role of SLC16A1 in urological cancer.

Frontiers in Oncology
Radical Cystectomy: Early-Stage Micropapillary Bladder Cancer Outcomes Similar to Late-Stage Conventional Urothelial Carcinoma

A study presented at the AUA 2021 Annual Meeting has found that among patients treated with radical cystectomy, those with cT1 micropapillary bladder cancer had similar or worse...

The ASCO Post
M6A Classification Combined With Tumor Microenvironment Immune Characteristics Analysis of Bladder Cancer

This study aims to investigate the role of m6A modification in TME cell infiltration of bladder cancer.

Frontiers in Oncology
Accelerated Approval Now Full for Pembro in Bladder Cancer

The new full approval is for pembroilizumab for first-line use for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for any platinum-containing chemotherapy.

Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma

Does inhibition of ataxia telangiectasia and Rad3 complement cisplatin-based chemotherapy for metastatic urothelial cancer?

JAMA Oncology
Multi-Omics Analysis of the Expression and Prognosis for FKBP Gene Family in Renal Cancer

This study aims to examine FKBPs prognostic value and molecular mechanism in clear cell renal cell carcinoma.

Frontiers in Oncology
Adjuvant Nivolumab Improves Disease-Free Survival in High-Risk Muscle-Invasive Urothelial Carcinoma

An interim analysis of the phase III CheckMate 274 trial has shown improved DFS with adjuvant nivolumab vs placebo among all patients and among those with tumor PD-L1 expression ≥ 1%.

The ASCO Post
Integrated Analysis of a Competing Endogenous RNA Network Reveals a Prognostic lncRNA Signature in Bladder Cancer

This study study comprehensively analyzes the differentially expressed RNA and corresponding ceRNA network and constructs a potentially predictive tool for prognosis.

Frontiers in Oncology
ctDNA Identifies Patients Who Benefit From Immunotherapy in MIUC

Among patients with muscle-invasive urothelial carcinoma, the presence of detectable ctDNA after surgery may identify those likely to benefit from adjuvant immunotherapy with the ICI atezolizumab.<

Reducing Immunotherapy Resistance in Prostate Tumors

Reprogramming immune cells inside tissues surrounding prostate tumors may improve response to checkpoint inhibitor therapy in patients, according to a new study.

Oncology Times - Latest Articles
Adjuvant Radiation May Provide a Survival Benefit Over Salvage Radiation in High-Risk Prostate Cancer

Adjuvant RT after radical prostatectomy may offer greater benefit than early salvage RT in men with high-risk prostate cancer, according to results of a study published in the Journal of Clinical..

Cancer Therapy Advisor
Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death

Investigators evaluate the impact of adjuvant versus early sRT on all-cause mortality risk in men with adverse pathology defined as positive pelvic lymph nodes or pGleason score 8-10 prostate cance

Journal of Clinical Oncology
Construction and Validation of a Novel Eight-Gene Risk Signature to Predict the Progression and Prognosis of Bladder Cancer

Study investigators establish a novel eight-gene risk signature that could predict the progression and prognoses of bladder cancer patients.

Frontiers in Oncology
How to Avoid Cystectomy in Muscle-Invasive Bladder Cancer

New data show that a large subset of patients with muscle-invasive bladder cancer can avoid cystectomy and enjoy long-term, bladder-intact, disease-free survival.

No Survival Difference for Front-Line Combination Regimens in Intermediate- and Poor-Risk Clear Cell RCC: Real-World Outcomes

A large retrospective study of real-world patients with RCC shows similar survival outcomes for patients with intermediate- or poor-risk disease regardless of whether they are treated with the comb

The ASCO Post
Can Smoking Cause Differences in Urine Microbiome in Male Patients With Bladder Cancer? A Retrospective Study

Study investigators explore the composition of male urinary microbiome and the correlation between tobacco smoking and microbiome in this study.

Frontiers in Oncology
Adjuvant Immunotherapy Benefit in Resected Kidney Cancer

For patients with high-risk clear-cell renal carcinoma who had undergone surgery, DFS is significantly longer if they received adjuvant pembrolizumab compared with placebo.

FDA Approves Piflufolastat F-18 Injection, a PSMA PET Imaging Agent, for the Detection of Metastatic or Recurrent Prostate Cancer

The FDA approves piflufolastat F-18 injection, an F-18–labeled PSMA-targeted positron-emission tomography imaging agent, to identify suspected metastasis or recurrence of prostate cancer.

The ASCO Post
Identification of an m6A-Related lncRNA Signature for Predicting the Prognosis in Patients With Kidney Renal Clear Cell Carcinoma

This study aims to construct an m6A-related long non-coding RNAs signature to accurately predict the prognosis of kidney clear cell carcinoma patients using data obtained from...

Frontiers in Oncology
Enfortumab Vedotin-ejfv After PD-1 or PD-L1 Inhibitor Therapy for Cisplatin-Ineligible Patients With Advanced Urothelial Carcinoma

This study shows a high response rate with the nectin-4–directed antibody-drug conjugate enfortumab vedotin-ejfv in cisplatin-ineligible patients with advanced or metastatic urothelial carcinoma...

The ASCO Post

source list reference

rgb(171, 222, 222)
200, 66, 245
rgb(195, 2, 230)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(242, 0, 137)
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
rgb(156, 242, 7)
rgb(224, 4, 129)
rgb(80, 147, 199)
rgb(5, 235, 235)
rgb(235, 190, 9)
rgb(209, 227, 11)
200, 66, 245
rgb(217, 7, 192)
rgb(2, 230, 230)